Loading organizations...
iPierian is a technology company.
iPierian was a biotechnology company focused on developing novel therapies for neurodegenerative diseases, particularly Tauopathies. It specialized in discovering monoclonal antibodies that targeted specific forms of the Tau protein. The company’s core technical approach leveraged proprietary induced pluripotent stem cell (iPSC) technology for the discovery of new therapeutic targets and the development of lead candidates like IPN007, an innovative preclinical antibody.
The company formed in 2009 through the strategic merger of iZUMI and Pierian, both entities with expertise in induced pluripotent stem cells. This combination capitalized on the pioneering scientific insights of researchers like Dr. George Daley, whose work included early advancements in human iPSC generation. The foundational idea was to utilize these patient-derived cells to model diseases and identify novel biological mechanisms for intervention.
iPierian aimed to serve patients suffering from a range of severe neurodegenerative conditions, including progressive supranuclear palsy, frontotemporal dementia, and Alzheimer's disease. Its vision was to translate its advanced stem cell research into effective antibody-based treatments, thereby offering new therapeutic options to address diseases with significant unmet medical needs.
iPierian has raised $129.0M across 6 funding rounds.
iPierian has raised $129.0M in total across 6 funding rounds.
iPierian has raised $129.0M in total across 6 funding rounds.
iPierian's investors include Beth Seidenberg, Jim Scopa, Rajeev Dadoo, Domain Associates, Endeavor Venture Funds, MPM Capital, SR One, Westlake Village BioPartners, FPV Fund, GV, ATEL Ventures, Biogen Idec New Ventures.
iPierian was a biotechnology company that developed novel therapeutics for neurodegenerative diseases using proprietary induced pluripotent stem cell (iPSC) technology. It reprogrammed patient-derived fibroblasts into iPSCs, differentiated them into disease-relevant cells like neurons and glia, and used these to identify disease phenotypes, validate targets, and discover drug candidates such as monoclonal antibodies against Tau protein targets, with a lead program IPN007 targeting secreted Tau.[1][2][3][7] The company served patients with conditions like Alzheimer's, ALS, Parkinson's, and Tauopathies, solving the challenge of studying early disease drivers inaccessible via traditional methods like autopsies, thereby improving clinical success rates for therapies.[1][3][8] Backed by investors including Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Highland Capital, and Google Ventures, iPierian achieved key milestones like spinning out True North Therapeutics before its acquisition by Bristol-Myers Squibb in 2014, marking strong early growth in the stem cell biotech space.[3]
Founded in 2007 in South San Francisco, iPierian pioneered the application of iPSC technology—recently advanced at the time—for drug discovery, making it the first company to use cellular reprogramming and directed differentiation on patient-derived cells across a broad spectrum of neurodegenerative diseases.[2][4][5] Key leadership included CEO Dr. Nancy Stagliano, who highlighted the company's breakthrough in secreted Tau biology underpinning IPN007.[3] The idea emerged from leveraging iPSCs to model diseases more accurately than end-stage autopsy samples, gaining early traction through high-profile funding and alliances focused on Tau pathways, culminating in the 2014 acquisition by Bristol-Myers Squibb to bolster its neurodegenerative expertise.[1][3][6]
iPierian rode the early 2010s wave of iPSC technology, enabled by Shinya Yamanaka's Nobel-winning work, to revolutionize neurodegenerative drug discovery amid a field plagued by high failure rates (over 99% for brain diseases).[2][6] Its timing capitalized on converging advances in stem cell reprogramming and the urgent need for better Alzheimer's and ALS models, as traditional rodent studies failed to translate clinically.[1][8] Market forces like aging populations and pharma giants' push into neuro (e.g., Bristol-Myers Squibb's acquisition) favored its platform, influencing the ecosystem by validating iPSC-derived human models—now standard in biotech for precision medicine and reducing animal testing reliance.[3][7]
Post-2014 acquisition, iPierian's iPSC platform and IPN007 integrated into Bristol-Myers Squibb's neuroscience pipeline, likely advancing Tau-targeted therapies amid ongoing neuro drug droughts.[3] Emerging trends like AI-driven target validation and CRISPR-enhanced iPSCs could amplify its legacy, shaping next-gen biotechs to prioritize human-cell models for faster, higher-success discoveries. As stem cell tech matures, iPierian's foundational work continues fueling the shift toward patient-specific therapeutics, underscoring how early biotech pioneers like it transform elusive diseases into addressable challenges.[1][2]
iPierian has raised $129.0M across 6 funding rounds. Most recently, it raised $30.0M Other Equity in September 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 4, 2013 | $30.0M Other Equity | Beth Seidenberg, Jim Scopa, Rajeev Dadoo | |
| Sep 1, 2013 | $30.0M Venture Round | Domain Associates, Endeavor Venture Funds, MPM Capital, SR One, Westlake Village BioPartners | |
| Nov 1, 2010 | $29.0M Series B | Domain Associates, Endeavor Venture Funds, FPV Fund, GV, MPM Capital, SR One, Westlake Village BioPartners | |
| Oct 1, 2010 | $6.0M Series B | Endeavor Venture Funds, ATEL Ventures, Biogen Idec New Ventures, FinTech Global Capital, Google Ventures, Highland Capital Partners, Kleiner Perkins, Mitsubishi UFJ Capital, MPM Capital, Rajeev Dadoo | |
| Jul 8, 2010 | $22.0M Series B | Krishna Yeshwant | ATEL Ventures, FinTech Global Capital, Highland Capital Partners, Kleiner Perkins, Mitsubishi UFJ Capital, MPM Capital |
| Jul 1, 2009 | $12.0M Venture Round | Domain Associates, Endeavor Venture Funds, MPM Capital, Westlake Village BioPartners |